• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    6/3/24 8:07:05 AM ET
    $ABIO
    $BGXX
    $BPTH
    $GPCR
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ABIO alert in real time by email

    Gainers

    • Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 70.4% to $3.51 during Monday's pre-market session. The market value of their outstanding shares is at $5.8 million.
    • Molecular Partners (NASDAQ:MOLN) shares moved upwards by 21.72% to $4.38. The company's market cap stands at $144.0 million.
    • Structure Therapeutics (NASDAQ:GPCR) shares moved upwards by 19.23% to $40.78. The company's market cap stands at $1.9 billion.
    • NewGenIvf Group (NASDAQ:NIVF) stock rose 16.78% to $1.6. The company's market cap stands at $16.2 million.
    • Kyverna Therapeutics (NASDAQ:KYTX) shares increased by 16.6% to $14.61. The market value of their outstanding shares is at $629.9 million.
    • ARCA biopharma (NASDAQ:ABIO) stock rose 15.4% to $4.27. The market value of their outstanding shares is at $61.9 million.

    Losers

    • Galera Therapeutics (NASDAQ:GRTX) stock decreased by 36.5% to $0.14 during Monday's pre-market session. The market value of their outstanding shares is at $7.4 million.
    • Portage Biotech (NASDAQ:PRTG) stock fell 20.99% to $0.38. The market value of their outstanding shares is at $7.4 million.
    • iSpecimen (NASDAQ:ISPC) stock declined by 17.4% to $0.36. The company's market cap stands at $3.5 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) shares declined by 15.5% to $1.5. The market value of their outstanding shares is at $9.9 million.
    • Bright Green (NASDAQ:BGXX) shares declined by 13.29% to $0.24. The market value of their outstanding shares is at $45.2 million.
    • Sonoma Pharmaceuticals (NASDAQ:SNOA) stock declined by 8.51% to $0.19. The company's market cap stands at $2.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABIO
    $BGXX
    $BPTH
    $GPCR

    CompanyDatePrice TargetRatingAnalyst
    Molecular Partners AG
    $MOLN
    1/27/2026$13.00Buy
    H.C. Wainwright
    Kyverna Therapeutics Inc.
    $KYTX
    8/20/2025Outperform
    William Blair
    Kyverna Therapeutics Inc.
    $KYTX
    5/27/2025$5.00Neutral → Buy
    H.C. Wainwright
    Structure Therapeutics Inc.
    $GPCR
    5/2/2025$60.00Buy
    Citigroup
    Structure Therapeutics Inc.
    $GPCR
    2/28/2025Outperform
    William Blair
    Structure Therapeutics Inc.
    $GPCR
    1/8/2025$50.00Buy
    Stifel
    Structure Therapeutics Inc.
    $GPCR
    12/4/2024$80.00Buy
    H.C. Wainwright
    Kyverna Therapeutics Inc.
    $KYTX
    10/10/2024$13.00Buy
    UBS
    More analyst ratings

    $ABIO
    $BGXX
    $BPTH
    $GPCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Molecular Partners AG with a new price target

    H.C. Wainwright initiated coverage of Molecular Partners AG with a rating of Buy and set a new price target of $13.00

    1/27/26 8:47:34 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    William Blair initiated coverage on Kyverna Therapeutics

    William Blair initiated coverage of Kyverna Therapeutics with a rating of Outperform

    8/20/25 8:57:26 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Kyverna Therapeutics from Neutral to Buy and set a new price target of $5.00

    5/27/25 9:06:20 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABIO
    $BGXX
    $BPTH
    $GPCR
    SEC Filings

    View All

    SEC Form S-8 filed by Structure Therapeutics Inc.

    S-8 - Structure Therapeutics Inc. (0001888886) (Filer)

    2/26/26 5:22:42 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Structure Therapeutics Inc.

    10-K - Structure Therapeutics Inc. (0001888886) (Filer)

    2/26/26 4:40:49 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Structure Therapeutics Inc. (0001888886) (Filer)

    2/26/26 4:11:24 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABIO
    $BGXX
    $BPTH
    $GPCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

    Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS II study with higher doses expected in Q1 2026  Aleniglipron Phase 3 initiation expected in 2H 2026 Initial data from the ongoing Phase 1 study of oral small molecule amylin receptor agonist ACCG-2671 and Phase 1 initiation of second oral amylin compound ACCG-3535 expected in 2H 2026 Cash, cash equivalents and short-term investments of $1.4 billion as of December 31, 2025, expected to provide cash runway through the end of 2028 SAN FRANCISCO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Structure Th

    2/26/26 4:02:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results

    ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced its attendance and presentations at upcoming investor conferences. Molecular Partners will also issue its full-year 2025 financial report, along with its Annual Report, on March 12, 2026. Details of the events: TD Cowen 46th Annual Health Care ConferenceBoston, MA, March 2-4, 2026Molecular Partners CEO Patrick Amstutz will take part in a fireside chat on Monday, March 2 at 2.30-3.00 pm E

    2/26/26 1:00:00 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics

    ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced it has entered into an agreement with Eckert & Ziegler, leading specialist in isotope-related components for nuclear medicine and radiation therapy, to enable the development and manufacturing of Radio-DARPin therapeutics. "We are pleased to work with Eckert & Ziegler, a global leader in radiopharmaceutical manufacturing. This agreement will expand the potential of Radio-DARPins as vecto

    2/26/26 1:00:00 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABIO
    $BGXX
    $BPTH
    $GPCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Seidenberg Beth C bought $999,998 worth of shares (133,333 units at $7.50) (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    12/22/25 11:43:43 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Westlake Biopartners Opportunity Fund I, L.P. bought $999,998 worth of shares (133,333 units at $7.50) (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    12/22/25 11:42:37 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Chang Nancy T bought $499,979 worth of shares (7,644,932 units at $0.07) (SEC Form 4)

    4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

    1/2/25 4:12:36 PM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABIO
    $BGXX
    $BPTH
    $GPCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Emany Sravan Kumar

    3 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    2/26/26 4:30:03 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Emany Sravan Kumar was granted 11,006 shares (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    2/26/26 4:30:04 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Pujols Mayobanex

    3 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    2/11/26 4:30:27 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABIO
    $BGXX
    $BPTH
    $GPCR
    Leadership Updates

    Live Leadership Updates

    View All

    Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

    Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization Andrew Miller adds deep clinical development and product approval experience to support Kyverna's next phase of growth EMERYVILLE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointments of Sravan K. Emany and Andrew Miller, Ph.D. to its Board of Directors. Mr. Emany will assume the role of Audit Committee Chair, following the transition of Dan Spiegelman from this position, who has stepped d

    2/24/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

    EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Mayo Pujols as its Chief Technology Officer (CTO), effective February 9, 2026. Mr. Pujols brings more than 30 years of technical operations experience to the role with a deep background in leading late-stage and commercial manufacturing for cell and gene therapies. His work spans both large-scale and smaller biopharmaceutical companies with a proven track record of successfully advancing programs across their lifecycles. He succeeds Karen Walker, who is

    2/3/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NIVF Appoints Award-Winning Web3 Leader Joshua Chu to Spearhead Tokenization Strategy and Formally Engages Evident Capital to Launch Up to USD 30 Million in Tokenized Bonds by Q1, Outlining 2026 Value Catalysts

    BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (("NewGen" or the "Company, NASDAQ:NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today announced the appointment of award-winning Web3 legal and regulatory specialist Joshua Chu as Senior Counsel to lead the Group's tokenization strategy, alongside the formal engagement of Evident Capital, Hong Kong's first fully integrated, SFC-licensed tokenization and alternative assets platform, to support the launch of NIVF's inaugural tokenized bond issuance of up to USD 30 million targeted for completion by the first quarter of 2026. As S

    1/21/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $ABIO
    $BGXX
    $BPTH
    $GPCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    12/5/24 8:23:57 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

    SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

    11/14/24 5:46:12 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Portage Biotech Inc.

    SC 13G/A - PORTAGE BIOTECH INC. (0001095435) (Subject)

    11/14/24 4:26:22 PM ET
    $PRTG
    Oil & Gas Production
    Energy

    $ABIO
    $BGXX
    $BPTH
    $GPCR
    Financials

    Live finance-specific insights

    View All

    Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

    Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancersDosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumorsMP0712 Phase 1/2a study open in U.S. with initial clinical data expected in 2026Molecular Partners to host conference call February 2 at 8AM ET (2PM CET), joined by renowned nuclear medicine expert Prof. Ken Herrmann, M.D. ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company deve

    2/2/26 1:00:00 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

    Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026  Miv-cel achieved statistically significant clinical benefit across all primary and secondary endpoints, reversing disability and eliminating immunotherapies after a single dose Miv-cel was generally well-tolerated with no high-grade CRS or ICANS observed SPS is a debilitating, progressive autoimmune disease with no FDA-approved therapies Company to host webcast today, December 15, 2025 at 8 am ET EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a c

    12/15/25 6:30:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

    EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will host a live webcast and conference call on Monday, December 15, 2025 at 8:00 am ET to review topline results from the registrational Phase 2 KYSA-8 clinical trial evaluating KYV-101 in stiff person syndrome (SPS). Conference Call Details Participants will need to register at the below-noted URL in order to listen and participate in the call. Once registered, participants will receive a dial-in phone number and unique PIN number which will be needed to join th

    12/14/25 2:30:00 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care